Abstract Human monoacylglycerol lipase (MGL) catalyzes the hydrolysis of 2-arachidonoylglycerol to arachidonic and glycerol, which plays a pivotal role in the normal biological processes of brain. Co-crystal structure of the MGL in complex with its inhibitor, compound 1, shows that the helix a4 undergoes large-scale conformational changes in response to the compound 1 binding compared to the apo MGL. However, the detailed conformational transition pathway of the helix a4 in the inhibitor binding process of MGL has remained unclear. Here, conventional molecular dynamics (MD) and nudged elastic band (NEB) simulations were performed to explore the conformational transition pathway of the helix a4. Conventional MD simulations unveiled that the compound 1 induced the closed conformation of the active site of MGL, reduced the conformational flexibility of the helix a4, and elicited the large-scale conformational rearrangement of the helix a4, leading to the complete folding of the helix a4. Moreover, NEB simulations revealed that the conformational transition pathway of helix a4 underwent an almost 180°c ounter-clockwise rotation of the helix a4. Our computational results advance the structural and mechanistic understanding of the inhibitory mechanism.
Introduction
2-Arachidonoylglycerol (2-AG), an endogenous ligand, acts as a potent agonist that activates G-protein-coupled cannabinoid receptors CB 1 and CB 2 , which are involved in diverse physiological processes encompassing mood, painsensation, and memory [1, 2] . 2-AG is tightly regulated by human monoacylglycerol lipase (MGL; EC 3.1.1.23), an ubiquitous 33 kDa, membrane-associated member of the serine hydrolase superfamily [3] [4] [5] . MGL contains the quintessential GXSXG, where X is any amino acid, conserved sequence shared by the vast majority of serine hydrolases. The three residues Ser122, His269, and Asp239 constitute the catalytic reaction center of MGL [3] .
The functional roles of MGL are tissue specific. In adipose tissue, MGL appears to follow the action of hormone-sensitive lipase to completely catalyze intracellular triglyceride to fatty acids and glycerol [6] . In the central nervous system (CNS), MGL hydrolyzes 2-AG to arachidonic and glycerol, which plays an essential role in the regulation of endocannabinoid signaling (Scheme 1) [7] . An overexpression of MGL in the CNS has been associated with various neurological diseases because immoderate hydrolysis of 2-AG impairs the physiological roles of CB 1 and CB 2 [8, 9] . These findings have motivated the development of MGL inhibitors, including a non-covalent inhibitor URB602 with low potency and selectivity for MGL [10] and irreversible covalent inhibitors such as 4-nitrophenyl-carbamate JZL184 [11] , N-arachidonylmaleimide [12] , and SAR629 [13] .
Recently, Schalk-Hihi et al. [14] reported a high-resolution structure of a soluble form of human MGL in complex with its reversible inhibitor, compound 1. This new co-crystal structure unveils a unique conformation of the regulatory lid-domain of MGL. By comparison of inhibitor-bound and unbound structures illustrates that the compound 1 induces a closed conformation of the regulatory important lid-domain. More specially, the helix a4 (residues 153-170) of the lid-domain undergoes a significant conformational change from the uncoiling state of the N-terminal residues (residues 153-157) in the apo MGL to the complete folding of the helix a4 in the compound 1-bound MGL (Fig. 1) . However, the detailed conformational transition pathway of the helix a4 in the inhibitor binding process has remained unclear.
Here, computational studies that integrate conventional molecular dynamics (MD) and nudged elastic band (NEB) simulations were conducted to explore the conformational transition pathway of the helix a4 in the inhibitor binding process of human MGL. The obtained results are not only of fundamental importance to understand the inhibitory mechanism of MGL, but also to design potent and selective MGL inhibitors.
Materials and Methods

Simulation Systems
Initial coordinates for the apo and compound 1-bound states of human MGL were taken from X-ray crystal structures (Protein Data Bank ID 3HJU [15] and 3PE6 [14] , respectively). In the inhibitor complex structure [14] , the three introduced mutations, K36A, L169S, and L176S, were mutated to native residues. Partial atomic charges for the compound 1 were calculated using the restricted electrostatic potential fitting protocol implemented in the Antechamber module of the AMBER 11 program [16] and following electrostatic potential calculations at ab initio HF/6-31G* level using Gaussian 09 program [17] . The protein was modeled using the AMBER FF03 force field [18] . For the simulations of MGL in aqueous solution, a truncated octahedral box of TIP3P waters [19] was added with a 10 Å buffer around the protein. The appropriate number of counter-ions was added to maintain the electroneutrality of the two systems.
Conventional MD Simulation
Energy minimizations, including steepest descent and conjugate gradient algorithms, were carried out to remove bad contacts in the initial structures using the previously reported protocol [20] [21] [22] . After relaxation, the two systems were heated from 0 to 300 K in 200 ps, which was followed by constant temperature equilibration at 300 K for 300 ps. Finally, 100 ns MD simulations were carried out for each system in an isothermal isobaric ensemble (NPT) with periodic boundary conditions. An integration step of 2 fs was set for the MD simulations, and the longrange electrostatic interactions were treated by the particle mesh Ewald (PME) method [23] . 10 Å was used for long range electrostatics and van der Waals interactions. The SHAKE method [24] was applied to constrain all covalent bonds involving hydrogen atoms. Each simulation was coupled to a 300 K thermal bath at 1.0 atm using the Langevin algorithm [25] .
Dynamical Cross-Correlation Matrices (DCCM)
The C a dynamical DCCM was calculated to uncover correlative motions of protein domains [26] . C(i,j) was computed be means of Eq. 
NEB Simulation
The NEB method [27, 28] was used to investigate the conformational transition pathway for the transformation between the apo and compound 1-bound MGL. In the NEB method, the transition pathway for a conformational change is connected by a string of replicas (or 'images') of the system. Minimization of the entire system, but with the start and the end point structures fixed, provides a minimum energy path. The forces F on each image i in NEB framework are projected to a perpendicular force and a parallel force using a tangent vector (s) along the path [Eq. (2)]. The perpendicular component of the force is obtained by subtracting out the parallel component of the force [Eq. (3)], where rV(P i ) is the gradient of the energy with respect to the atomic coordinates in the system at image i. The parallel component of the force accounts for the artificial springs linking each image together [Eq. (4)], where k i is equal to the spring constant between images P i and P i-1 , and P is the 3 N dimensional position vector of image i.
In the NEB simulation implemented in AMBER 11, the start and end points were taken from the energy-minimized structures of the apo and compound 1-bound MGL from the conventional MD simulations. The initial NEB pathway was composed of eleven staring points followed by eleven end points. The initial path was heated from 0 to 300 K in 300 ps with spring force of 10 kcal mol -1 Å -2 and Langevin dynamics collision frequency of 1,000 ps -1 . Subsequently, the path was equilibrated at 300 K in 500 ps with spring force of 50 kcal mol -1 Å -2 . After that, 1,010 ps of simulated annealing protocol to calculate minimal energy path with NEB (Table S1 ) contained quickly heating the path to 500 K, followed by slow cooling to 0 K with the spring force of 50 kcal mol -1 Å -2 . Finally, 1,000 ps of quenched MD at 0 K were performed to remove any remaining kinetic energy from the path.
Results
The crystal architecture of human MGL presents a conserved folding motif named the a/b-hydrolase fold, which is characterized by eight b-sheets including seven parallel strands and one antiparallel strand encased by eight ahelices (Fig. 1) . The lid-domain of MGL consists of residues 151-225 from helices a4-a6, which controls substrates access to the active site. The inhibitor, compound 1, occupies an extended binding site, proximal to helices a4, a6, a7, and a5. The structural characteristics of the apo and compound 1-bound MGL were first probed using conventional MD simulations.
Protein Stability and Residue Flexibility
Conventional MD simulations of the two systems, apo MGL and MGL-compound-1, were first performed for Conformational Transition Pathway in the Inhibitor Binding Process 505 100 ns. The C a atoms of proteins of the root-mean-square deviation (RMSD) compared to the initial structure was assessed. As shown in Fig. 2a , the C a atoms RMSD plot for the apo MGL seemed to equilibrate at *5 ns, with the RMSD value of 1.9 ± 0.3 Å . In a similar vein, the C a atoms RMSD plot for the MGL-compound-1 complex also tended to equilibrate at *5 ns, with the RMSD value of 1.4 ± 0.1 Å . These data indicate that the apo MGL exhibits a larger conformational flexibility compared with the MGL-compound-1 complex. The thermodynamic stability of the two simulated systems can be characterized by their root-mean-square fluctuation (RMSF) values be virtue of the calculation of the C a atoms fluctuations of each residue around its average position. As shown in Fig. 2b , the residues fluctuations in the apo MGL are generally similar with the MGL-compound-1 complex with the exception of the region in the lid-domain (helix a4 and the loop connecting to a5; residues 153-187 with which the inhibitor interacts), which displays markedly higher RMSF values in the apo MGL compared to the MGL-compound-1 complex.
Ligand-Induced Closed Conformation of MGL
The superimpositions of the average structures of the apo and compound 1-bound MGL revealed that the compound 1 induced a closed conformation of the active site of MGL, whereas the open conformation was presented in the apo MGL (Fig. 3a) . To ascertain this distinct dynamic behavior, the C a atoms distance between Phe159 from the helix a4 and Gly210 from the helix a6 was monitored during MD simulations. As shown in Fig. 3b , the Phe159ÁÁÁGly210 distance was calculated to be 14.7 ± 0.7 Å in the apo MGL, indicative of the open conformation of the active site of MGL. In contrast, this distance was calculated to be 7.8 ± 0.3 Å in the compound 1-bound MGL, indicative of the closed conformation of the active site of MGL. In the quest of further elucidating the ligand binding on the conformational dynamics of MGL, the influence of correlative motions due to the binding of compound 1 to MGL were evaluated. As shown in Fig. 3c , the results of DCCM indicated that the overall dynamics of the apo and compound 1-bound MGL were very similar to each other. However, inspection of DCCM results between the apo and compound 1-bound MGL unearthed that the compound 1 exerted a significant effect on the conformational dynamics of MGL in several regions; in the apo MGL, the helices a4 and a6 that encase the active site of MGL had strong anticorrelated movements, representing by dark blue, whereas in the compound 1-bound MGL, the anti-correlated movements of the C-lobes significantly reduced after ligand binding. Taken together, these data indicated that the conformational plasticity of the helix a4 was attenuated after the ligand binding.
Ligand-Induced Complete Folding of Helix a4
Another pronounced structural difference between the average structures of the apo and compound 1-bound MGL emphasized that the helix a4 (residues 158-170), coupled Fig. 2 a The RMSD for the C a atoms of the apo and compound 1-bound MGL during the 100 ns MD simulations. b The calculated RMSF values for the C a atoms of the apo and compound 1-bound MGL with the uncoiling residues 153-157 at its N-terminus in the apo MGL completely integrated into the new helix a4 (residues 153-170) in the compound 1 bound MGL (Fig. 3a) . To further address this phenomenon, secondary structure analysis was carried out on residues Pro153 to Val170 for the two simulated systems by the defined secondary structure of proteins (DSSP) algorithm [29] . Figure 4 shows the secondary structure profiles of residues Pro153 to Val170. The native turn secondary structure at residues Pro153 to Thr157 in the apo MGL was converted into an a-helical structure in the compound 1-bound MGL, leading to a complete folding of the helix a4 (residues 153-169) in the ligand bound MGL. In a-helices, a regular pattern of hydrogen bonds exists between an amide carbonyl of residue i (the acceptor) and the amide H ? donor of residue i ? 4 (C i = OÁÁÁH-N i?4 ). The hydrogen bond contacts were characterized by percentage of occurrence data [30] [31] [32] . The analysis indicated that the
Thr157 was maintained with 100 % occurrence in the compound 1-bound MGL during the MD simulations, whereas in the apo MGL the occurrence of this hydrogen bond was 0 %, in accordance with the results of DSSP. In addition, the angle among the C a atoms of Pro153, Thr157, and Val161 that orient the same direction located in the helix a4 of the compound 1-bound MGL was monitored in the two systems during the MD simulations. As shown in Fig. 5 , the calculated angle was 125.2°± 7.5°i n the apo MGL, revealing the bending of the helix a4. In contrast, it was nearly linear in the compound 1-bound MGL, with the value of 173.1°± 4.1°, revealing the complete folding of the helix a4 induced by the compound 1. Figure 6 shows the angle landscape among the C a atoms of Pro153, Thr157, and Val161 located in the helix a4 along the transition pathway based on the twenty-two images stemmed from the NEB trajectory. Inspection of the representative snapshots, the process for the conformational transition pathway of helix a4 can be described by the following four states. Figure 6A represents the initial state of helix a4, in which the N-terminal helix a4 (residues 153-157) exhibited the turn secondary structure. In this state, the helix a4 was bending, with the angle (C a
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ÁÁÁC a
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ÁÁÁC a Val161 ) of 124.3°. Then, the C-terminal helix a4 (residues 158-170) was counter-clockwise rotation (viewed from C to N-terminus), leading to a local maximum of the bending angle of helix a4, with the value of 150.1° (Fig. 6B) . After that, the C-terminal helix a4 was continued to counter-clockwise rotation, coupled with the uncoiling of its several helical residues (residues 158-161) at the start of the C-terminus, giving rise to a local minimum of the bending angle of helix a4, with the value of 129.9° (Fig. 6C) . Eventually, the N-terminal residues (153-160) of helix a4 were counter-clockwise rotated to completely fold into an a-helix, which results the maximum angle of 172.9°corresponding to the product structure (Fig. 6D ).
Discussion
Human MGL has been implicated in the regulation of several cellular events. Inhibition of the aberrant MGL function by inhibitors is emerging as a potential strategy that can be applied to a number of diseases. However, the mechanism of conformational transition pathway for the helix a4 of human MGL in the inhibitor binding process remains unclear. In this article, conventional MD and NEB simulations were carried out to investigate the crystal structure complex of human MGL along with its inhibitor compound 1 to provide insight into the conformational transition pathway of the helix a4.
In the crystal structure of the apo human MGL [15] , the protein crystallized in I222 space group as a dimer, with the two monomers per asymmetric unit. This structure represents an open form. Analysis of the interface interactions in this structure shows that the lid-domain is distant from the interface. In the crystal structure of the bound human MGL [14] , the protein crystallized in C222 1 space group as a monomer. This structure represents a closed form. The solution of both open and closed forms of MGL supports the interfacial activation of MGL that allows the enzyme to exist in two main conformational states, an open and a closed forms [15] . Using large-scale MD simulations, Rengachari et al. [33] also observed the existence of the stable open and closed conformations of MGL in solution. Furthermore, detailed comparison between the apo and bound forms reveals that the lid-domain undergoes a substantial rearrgemnet upon ligand binding with other regions showing only very small differences [14] . The above data may indicate that MGL can exist in the open and closed forms and the conformational change of the lid region may be induced by ligand binding.
Previously, Rengachari et al. [33] solved the crystal structures of MGL from the bacterium Basillus sp. H257 in the apo form (PDB ID: 3RM3) and in complex with phenylmethylsulfonyl fluoride (PDB ID: 3RLI). Remarkably, the [33] .
The RMSD plots of the apo MGL and MGL-compound-1 complex suggest that the two systems were stable during the 100 ns MD simulations. Lower RMSD values were obtained in the MGL-compound-1 complex compared to the apo MGL indicates that the compound 1 plays a fundamental role in the stability of MGL. The calculation of RMSF has the ability to detect rigid and fluctuating residues in protein structure. It should be noted that the notable changes were observed in the lid-domain, while the other domains showed only very small differences. The higher RMSF values in the apo MGL accentuate the inherent flexibility of the lid-domain, which probably facilitates its displacement from the surface of the membrane during the ligand binding [14] . Analysis of the MD trajectories between the apo MGL and MGL-compound-1 complex showed that the compound 1 induced the closed conformation of the active site of MGL and the complete folding of the helix a4.
Conventional all-atom MD simulations of biomacromolecules embedded in the explicit solvent have the potential to capture large conformational rearrangement to sample conformational ensembles at atomic level [34] [35] [36] [37] . Of note, large-scale MD simulations are extraordinarily time-consuming [34] . Thus, NEB, a powerful algorithm that has been successful to explore large conformational changes in human glucokinase [38] and 23S rRNA [39] , was used to investigate the conformational transition pathway of helix a4 induced by the compound 1. Based on the results from NEB simulations, we revealed that in the overall process of folding (Supporting Information Video S1), an almost 180°counter-clockwise rotation of the helix a4 was observed in the compound 1-bound state compared to the apo state, rendering the residues Pro153, Thr157, and Val161 point to the same direction. The resulting conformational transition of helix a4 induced by the compound 1 may change the electrostatic surface of helix a4, thereby leading to the MGL dissociation from the membrane upon completion of the catalytic cycle [14] .
Conclusions
Here, conventional MD and NEB simulations were carried out to investigate the conformational transition pathway of the helix a4 in the inhibitor binding process of human MGL. Conventional MD simulations revealed that binding of compound 1 to the active site of MGL enabled to reduce the RMSF values of the lid-domain. Furthermore, founded on the distance analysis between the helices a4 and a6 and the DCCM analysis, the compound 1 induced the closed conformation of the active site of MGL and reduced the conformational flexibility of the helix a4. Specially, the analyses of DSSP of the helix a4 and the helical bending angle (C a Pro153 ÁÁÁC a Thr157 ÁÁÁC a
Val161
) between the apo and compound 1-bound MGL demonstrated that the compound 1 induced the large-scale conformational rearrangement of the helix a4, leading to the complete folding of the helix a4. Moreover, NEB simulations unveiled that the conformational transition pathway of helix a4 from the uncoiling state of the N-terminal residues (residues 153-157) in the apo MGL to the complete folding of the helix a4 in the compound 1-bound MGL underwent an almost 180°counter-clockwise rotation of the helix a4. These results will provide an opportunity to further optimize the interactions between the MGL and its non-covalent inhibitions to design more potent and selective MGL inhibitors.
